Darshan.K, Correspondent, India Pharma Outlook Team
The Pfizer- BioNtech and Moderna COVID-19 Vaccines both Utilized mRNA technology, and their entire process, right from the development to deployment, was completed in less than a year. This was a record-breaking feat considering how vaccines normally took years to develop. This event was one of the biggest accomplishments in modern medicine.
Experts recognize the potential of RNA-based therapeutics, consisting of both messenger RNA (mRNA) and small interfering RNA (siRNA), in addressing the wide range of medical conditions that currently have no treatments. Here, we explore the ways the medical professionals believe it’ll revolutionize modern medicine.
One of the major breakthroughs in RNA-based therapeutics is the utilization of mRNA to direct cellular protein synthesis. This pioneering take has garnered extensive attention, notably the success of mRNA COVID-19 vaccines. Experts acknowledge the versatility of mRNA, which can be engineered to produce a wide array of proteins, including those that play vital roles in disease pathways.
mRNA therapeutics are currently being explored for various applications ranging from cancer immunotherapy to genetic disorders. Personalized mRNA vaccines in cancer treatment are currently in development to stimulate the patient’s immune systems to target and destroy cancer cells. The ability to customize vaccines to an individual’s unique genetic profile holds tremendous potential for effective cancer treatments. Moreover, researchers are investigating mRNA treatments for genetic disorders, where the introduction of functional mRNA can compensate for defective or missing proteins. Diseases like cystic fibrosis and certain types of muscular dystrophy are being targeted, offering hope for patients with previously limited treatment options.
The exact causes of auto-immune diseases cannot be pinpointed, most factors point to the fact that it is genetic. siRNA therapies take the “prevention is better than cure approach” by silencing the genes associated with the disease itself. This technology has demonstrated significant potential in treating a variety of malfunctioning gene-caused conditions.
Neurodegenerative disease treatments are now being explored with siRNA therapies to target genes responsible for the accumulation of toxic proteins, which is a signature of conditions like Alzheimer's and Parkinson's disease. By ‘Shutting down’ the production of these proteins, this therapy offers an original strategy to halt or slow down the degenerative progression.
siRNA has proven itself in its ability to combat viral infections. Researchers are now developing treatments based on its properties which can precisely target and obstruct the replication of viruses, presenting itself as an antidote for rapidly evolving pathogens. This approach
In the field of infectious diseases, siRNA has shown promise in combating viral infections. Researchers are developing siRNA-based treatments that can specifically target and inhibit the replication of viruses, presenting a versatile tool against rapidly evolving pathogens. This approach could revolutionize our ability to respond to emerging infectious diseases.
Alnylam Pharmaceuticals is Pioneering RNA interference (RNAi) therapeutics, they developed Onpattro, the first FDA-approved siRNA therapeutic for hereditary transthyretin-mediated amyloidosis.
It has been observed that it is difficult to deliver RNA molecules to specific cells throughout the body while avoiding immune system degradation. Researchers are actively developing advanced delivery systems, such as lipid nanoparticles, to improve the stability and targeted delivery of RNA therapies.
Furthermore, ensuring the safety of these treatments is critical. Patients may be at risk if they experience unintended immune responses or off-target effects. Ongoing research is focused on improving the design of RNA molecules and delivery systems to reduce potential side effects and maximize therapeutic outcomes.
Acuitas Therapeutics is known for its contribution to the development of lipid nanoparticles (LNPs), they specialize in RNA delivery systems, addressing challenges related to stability and targeted delivery.
The future of medicine has shown itself to be increasingly personalized, with RNA-based therapeutics playing a central role. The ability to tailor treatments based on an individual's genetic makeup holds the potential to revolutionize patient outcomes, offering more effective and targeted interventions.
Beyond personalized medicine, the versatility of RNA-based therapeutics opens avenues for treating previously challenging conditions. Rare genetic disorders, neurodegenerative diseases, and viral infections are seeing groundbreaking advancements, transforming the way we approach and manage these conditions.
CureVac N.V. is Focusing on developing mRNA-based therapies, CureVac explores personalized medicine applications, including cancer immunotherapy and infectious disease vaccines.
Collaboration between academia, pharmaceutical companies, and regulatory bodies is crucial for the continued development and eventual widespread adoption of RNA-based therapeutics. The regulatory landscape will need to evolve to accommodate the unique characteristics of these therapies, ensuring that they meet rigorous safety and efficacy standards.
, CDSCO.jpg)
